Gene Biotherapeutics Stock Forecast, Price & News

0.00 (0.00 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume533,645 shs
Average Volume766,515 shs
Market Capitalization$785,358.00
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CRXM News and Ratings via Email

Sign-up to receive the latest news and ratings for Gene Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Gene Biotherapeutics logo

About Gene Biotherapeutics

Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies to manufacture the Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.65 out of 5 stars

Medical Sector

1364th out of 2,097 stocks

Biological Products, Except Diagnostic Industry

167th out of 198 stocks

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Gene Biotherapeutics (OTCMKTS:CRXM) Frequently Asked Questions

What stocks does MarketBeat like better than Gene Biotherapeutics?

Wall Street analysts have given Gene Biotherapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Gene Biotherapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Gene Biotherapeutics?

Gene Biotherapeutics saw a increase in short interest in May. As of May 28th, there was short interest totaling 82,100 shares, an increase of 269.8% from the May 13th total of 22,200 shares. Based on an average trading volume of 1,574,700 shares, the days-to-cover ratio is presently 0.1 days.
View Gene Biotherapeutics' Short Interest

How has Gene Biotherapeutics' stock been impacted by Coronavirus?

Gene Biotherapeutics' stock was trading at $0.16 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CRXM stock has decreased by 66.1% and is now trading at $0.0542.
View which stocks have been most impacted by COVID-19

Who are Gene Biotherapeutics' key executives?

Gene Biotherapeutics' management team includes the following people:
  • Mr. Christopher J. Reinhard, Co-Founder, CEO, Pres, Treasurer, Sec. & Director (Age 67, Pay $239k)
  • Mr. James L. Grainer, Chairman, CFO & Sec. (Age 66)
  • Dr. Lois A. Chandler, Chief Operating Officer (Age 63)
  • Dr. Ronald J. Shebuski, Chief Scientific Officer (Age 68)
  • Mr. Duane Linstrom, Gen. Counsel
  • Mr. Kelly D. Scott, VP of Bus. Devel. of Medtech Bus. Unit and EVP of Inner Cool Therapies Inc (Age 65)

Who are some of Gene Biotherapeutics' key competitors?

What other stocks do shareholders of Gene Biotherapeutics own?

What is Gene Biotherapeutics' stock symbol?

Gene Biotherapeutics trades on the OTCMKTS under the ticker symbol "CRXM."

How do I buy shares of Gene Biotherapeutics?

Shares of CRXM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gene Biotherapeutics' stock price today?

One share of CRXM stock can currently be purchased for approximately $0.05.

How much money does Gene Biotherapeutics make?

Gene Biotherapeutics has a market capitalization of $785,358.00.

How many employees does Gene Biotherapeutics have?

Gene Biotherapeutics employs 4 workers across the globe.

What is Gene Biotherapeutics' official website?

The official website for Gene Biotherapeutics is www.cardiumthx.com.

Where are Gene Biotherapeutics' headquarters?

Gene Biotherapeutics is headquartered at 11568 SORRENTO VALLEY ROAD SUITE 14, SAN DIEGO CA, 92121.

How can I contact Gene Biotherapeutics?

Gene Biotherapeutics' mailing address is 11568 SORRENTO VALLEY ROAD SUITE 14, SAN DIEGO CA, 92121. The company can be reached via phone at 858-436-1000 or via email at [email protected]

This page was last updated on 6/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.